Skandinaviska Enskilda Banken AB publ Reduces Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Skandinaviska Enskilda Banken AB publ trimmed its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 76.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,512 shares of the biotechnology company’s stock after selling 11,200 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in Sarepta Therapeutics were worth $273,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Point72 Asset Management L.P. purchased a new stake in shares of Sarepta Therapeutics in the 1st quarter worth about $10,359,000. Advisors Asset Management Inc. increased its stake in shares of Sarepta Therapeutics by 49.5% in the 1st quarter. Advisors Asset Management Inc. now owns 20,446 shares of the biotechnology company’s stock worth $1,524,000 after acquiring an additional 6,771 shares in the last quarter. Canada Pension Plan Investment Board bought a new position in shares of Sarepta Therapeutics in the 1st quarter worth about $365,000. Sivik Global Healthcare LLC bought a new position in shares of Sarepta Therapeutics in the 1st quarter worth about $1,491,000. Finally, Acadian Asset Management LLC bought a new position in shares of Sarepta Therapeutics in the 1st quarter worth about $285,000. 79.33% of the stock is owned by hedge funds and other institutional investors.

SRPT opened at $87.47 on Thursday. The company has a current ratio of 5.33, a quick ratio of 4.70 and a debt-to-equity ratio of 2.25. The company has a market cap of $6.98 billion, a price-to-earnings ratio of -10.91 and a beta of 1.38. The company’s 50 day moving average is $76.26 and its 200 day moving average is $76.38. Sarepta Therapeutics, Inc. has a 12-month low of $65.30 and a 12-month high of $181.83.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, August 4th. The biotechnology company reported ($1.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.29) by $0.27. The company had revenue of $164.09 million for the quarter, compared to the consensus estimate of $161.95 million. Sarepta Therapeutics had a negative net margin of 105.73% and a negative return on equity of 94.90%. The firm’s revenue was up 19.5% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.93) earnings per share. As a group, analysts predict that Sarepta Therapeutics, Inc. will post -7.46 EPS for the current fiscal year.

SRPT has been the subject of several research reports. Zacks Investment Research upgraded shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating and set a $84.00 price target for the company in a research note on Wednesday, August 11th. JPMorgan Chase & Co. upgraded shares of Sarepta Therapeutics from an “underweight” rating to a “neutral” rating and decreased their price target for the stock from $92.00 to $87.00 in a research note on Thursday, August 5th. Berenberg Bank assumed coverage on shares of Sarepta Therapeutics in a research note on Thursday, July 1st. They set a “hold” rating and a $85.00 price objective for the company. Credit Suisse Group raised their price objective on shares of Sarepta Therapeutics from $72.00 to $75.00 and gave the company a “neutral” rating in a research note on Thursday, August 5th. Finally, BTIG Research assumed coverage on shares of Sarepta Therapeutics in a research note on Monday, June 14th. They set a “buy” rating and a $110.00 price objective for the company. Eleven analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $125.39.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Further Reading: Yield Curve

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.